Form 8-K - Current report:
SEC Accession No. 0001437749-24-033929
Filing Date
2024-11-07
Accepted
2024-11-07 16:14:48
Documents
16
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20241106_8k.htm   iXBRL 8-K 27377
2 EXHIBIT 99.1 ex_744159.htm EX-99.1 206670
7 logo.jpg GRAPHIC 5130
  Complete submission text file 0001437749-24-033929.txt   393503

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20241107.xsd EX-101.SCH 3410
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20241107_def.xml EX-101.DEF 11808
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20241107_lab.xml EX-101.LAB 15859
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20241107_pre.xml EX-101.PRE 12023
18 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20241106_8k_htm.xml XML 2944
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

EIN.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 241435918
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)